AU - Patil, Shashank AU - Kumari, V AU - Shirahatti, Prithvi AU - Sujay, S AU - Tejaswini, M AU - Ranganath, Lakshmi AU - Jayanthi, M AU - Ramu, Ramith TI - COVID-19 infection: The prospects of pharmacotherapy PT - COMM DP - 2020 Apr 1 TA - International Journal of Health & Allied Sciences PG - 111-113 VI - 9 IP - 5 4099- https://www.ijhas.in/article.asp?issn=2278-344X;year=2020;volume=9;issue=5;spage=111;epage=113;aulast=Patil;type=0 4100- https://www.ijhas.in/article.asp?issn=2278-344X;year=2020;volume=9;issue=5;spage=111;epage=113;aulast=Patil AB - The disastrous outbreak of coronavirus disease 2019 (COVID-19) has triggered the investigation of several therapeutic options following the redundancy of specific drugs against it. The virus possesses advanced molecular mechanisms to effectively invade the host cell compared to its counterparts. It results in a seamless and coherent infection and transmission, attributing to its enhanced pathogenicity. The drugs that are currently being employed against COVID-19 inhibit the viral load in different stages of infection, including host cell–virus interaction, viral entry into the host cell, and viral replication inside the host including genome replication and polypeptide chain production. This commentary emphasizes the pharmacotherapeutic options available from the perspective of viral life cycle and pathogenicity.